All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

When is a second CAR T-cell infusion feasible for patients who failed prior CAR T-cell therapy?

Featured:

Jordan GauthierJordan Gauthier

Feb 10, 2021


During the 3rd European CAR T-cell Meeting, the Lymphoma Hub spoke to Jordan Gauthier, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, When is a second CAR T-cell infusion feasible for patients who failed prior CAR T-cell therapy?

When is a second CAR T-cell infusion feasible for patients who failed prior CAR T-cell therapy?

For patients who do not respond to the first round of CAR T-cell infusion, the best course of treatment is unknown but one option is to give a second dose. In this video, Jordan Gauthier discusses the data from 44 patients with B-cell malignancies.

Your opinion matters

What is your preferred therapy class when planning treatment for a patient with R/R DLBCL after 2 or more lines of systemic therapy ?